Diagnostik bei invasiven Mykosen: What’s hot?

Invasive Pilzinfektionen sind eine wesentliche Ursache für Morbidität und Letalität bei Patient*innen mit Abwehrschwäche. Die wichtigsten und häufigsten Pathogene in Europa sind Aspergillus- und Candida-Spezies. Zunehmend werden aber auch Mucorales-, Trichosporon- und Fusarium-Spezies nachgewiesen. Die gesicherte Diagnose einer invasiven Mykose ist schwierig. Neben Bildgebung und Klinik sind Grundelemente der Diagnostik die konventionelle Pilzkultur, Mikroskopie, Antikörper-/Antigen-Suchtests und Molekularbiologie.

Abstract

Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised patients. The primary and most frequent pathogens in Europe are Aspergillus and Candida species. However, other representatives such as Mucorales, Trichosporon, and Fusarium species are increasingly being identified. Confirming the diagnosis of an invasive mycosis is challenging; apart from imaging and clinical presentation, essential diagnostic elements include conventional fungal culture, microscopy, antibody/antigen detection tests, and molecular biology.

Kernaussagen

• Die Auswahl diagnostischer Tests hängt in der Regel von der Patientenpopulation, der Vortest-Wahrscheinlichkeit der Infektionskrankheit, der Laborausstattung und der regionalen Expertise ab.

• Es gibt keinen einzelnen Test, der alle diagnostischen Anforderungen erfüllt und alle Pilze abdeckt, daher wird ein „Puzzle-Diagnoseansatz“ empfohlen.

• Biomarker werden verwendet, um bei der Diagnose zu unterstützen, anstatt eine endgültige Diagnose festzustellen.

• Prinzipiell sind Biomarker nur bei Risikopatient*innen bzw. bei Verdacht auf eine spezielle Infektion einzusetzen. Alle Ergebnisse müssen im Kontext einer Erkrankung gesehen werden.

• Der Einsatz diagnostischer Tests und deren korrekte Interpretation sollten im Rahmen eines „Antibiotic-Stewardships“ festgelegt werden.

Schlüsselwörter

nvasive Pilzinfektionen - Diagnostik - Mikroskopie - Biomarker

Keywords

invasive mycoses - diagnostics - fungal microscopy - biomarker

Publication History

Article published online:
24 April 2024

• Literatur

• 1 Stemler J, Mellinghoff SC, Khodamoradi Y. et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother 2023; 78: 1813-1826
• 2 Verweij PE, Bruggemann RJM, Azoulay E. et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med 2021; 47: 819-834
• 3 Lynch JP, Kontoyiannis DP. Special Issue “Diagnosis and treatment of invasive pulmonary fungal infections”. J Fungi (Basel) 2023; 9: 744
• 4 Lass-Flörl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med 2023; 94: 101215
• 5 Lass-Flörl C, Samardzic E, Knoll M. Serology anno 2021-fungal infections: from invasive to chronic. Clin Microbiol Infect 2021; 27: 1230-1241
• 6 Lass-Flörl C. How to make a fast diagnosis in invasive aspergillosis. Med Mycol 2019; 57: S155-S160
• 7 Lackner N, Posch W, Lass-Flörl C. Microbiological and molecular diagnosis of mucormycosis: from old to new. Microorganisms 2021; 9: 1518
• 8 Friedman DZP, Schwartz IS. Emerging diagnostics and therapeutics for invasive fungal infections. Infect Dis Clin North Am 2023; 37: 593-616
• 9 Bloos F, Held J, Kluge S. et al. (1 → 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med 2022; 48: 865-875
• 10 Ullmann AJ, Aguado JM, Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24: E1-E38
• 11 Stemler J, Tobben C, Lass-Flörl C. et al. Diagnosis and treatment of invasive aspergillosis caused by non-fumigatus Aspergillus spp. J Fungi (Basel) 2023; 9: 500
• 12 Classen AY, Henze L, von Lilienfeld-Toal M. et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021; 100: 1603-1620
• 13 Posch W, Heimdorfer D, Wilflingseder D. et al. Invasive candidiasis: future directions in non-culture based diagnosis. Expert Rev Anti Infect Ther 2017; 15: 829-838
• 14 Knoll MA, Steixner S, Lass-Flörl C. How to use direct microscopy for diagnosing fungal infections. Clin Microbiol Infect 2023; 29: 1031-1038
• 15 Tissot F, Agrawal S, Pagano L. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102: 433-444
• 16 Govrins M, Lass-Flörl C. Candida parapsilosis complex in the clinical setting. Nat Rev Microbiol 2024; 22: 46-59
• 17 White PL, Alanio A, Brown L. et al. An overview of using fungal DNA for the diagnosis of invasive mycoses. Expert Rev Mol Diagn 2022; 22: 169-184
• 18 Blauwkamp TA, Thair S, Rosen MJ. et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol 2019; 4: 663-674
• 19 Heldman MR, Ahmed AA, Liu W. et al. Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant. J Infect Dis 2023;
• 20 Van TT, Kim TH, Butler-Wu SM. Evaluation of the Biofire FilmArray meningitis/encephalitis assay for the detection of Cryptococcus neoformans/gattii. Clin Microbiol Infect 2020; 26: 1375-1379
• 21 Li H, Gao H, Meng H. et al. Detection of pulmonary infectious pathogens from lung biopsy tissues by metagenomic next-generation sequencing. Front Cell Infect Microbiol 2018; 8: 205